Enveric Biosciences (NASDAQ: ENVB) is leveraging their discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and chemistry, the company is taking what Nature created and optimizing it for the Human Condition. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from cancer-related distress, PTSD and more.
• Powerful IP portfolio - 14 Patents filed
• Multi-billion-dollar opportunities with large patient populations in mind and body
• Psybrary contains 1M+ molecules encompassing Gen2 and Gen3, including non-hallucinogenics
• PsyAI allows us allows us to target indications and accelerate pathway to an IND
• Experienced Team from Discovery through Phase 3 Clinicals
• Strong Financial Position:$20M in cash and NASDAQ traded